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Despite the impressive progress over the past decade, in the ﬁeld of tumor immunology,
such as the identiﬁcation of tumor antigens and antigenic peptides, there are still many
obstacles in eliciting an effective immune response to eradicate cancer. It has become
increasingly clear that tumor microenvironment plays a crucial role in the control of immune
protection.Tumors have evolved to utilize hypoxic stress to their own advantage by activat-
ing key biochemical and cellular pathways that are important in progression, survival, and
metastasis. Hypoxia-inducible factor (HIF-1) and vascular endothelial growth factor (VEGF)
play a determinant role in promoting tumor cell growth and survival. Hypoxia contributes
to immune suppression by activating HIF-1 and VEGF pathways. Accumulating evidence
suggests a link between hypoxia and tumor tolerance to immune surveillance through the
recruitment of regulatory cells (regulatory T cells and myeloid derived suppressor cells).
In this regard, hypoxia (HIF-1α and VEGF) is emerging as an attractive target for cancer
therapy. How the microenvironmental hypoxia poses both obstacles and opportunities for
new therapeutic immune interventions will be discussed.
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INTRODUCTION
Cancer vaccines are expected to augment already established anti-
tumor immune responses and to induce de novo immunity or
reverse tolerance. Major advances have led to several immuniza-
tion strategies to boost immune responses against some tumor-
associated antigens. In this regard, strategies involving various
forms of peptides either alone or in combination with different
cytokines, adjuvant, or dendritic cells have been used to enhance
speciﬁc immune responses. Despite the enthusiasm for current
vaccination approaches, it should be noted that tumor rejection
in patients does not always follow successful induction of tumor-
speciﬁc immune responses by cancer vaccines. Even, if a strong and
sustained cytotoxic response is induced, complex issues remain
such as tumor evasion, tolerance and selection of tumor resis-
tant variants (Rosenberg et al., 1998, 2004; Hamai et al., 2010).
Nevertheless, systemic administration of monoclonal antibodies
targeting immune modulatory receptors: cytotoxic T-lymphocyte
antigen 4 (CTLA-4; Eggermont et al., 2010) and Programmed
Death 1 (PD1) on T reg and effector cells have been recently
reported to increase anti-tumor immunity both experimentally
and clinically (Alexandrescu et al., 2010; Callahan et al., 2010;
Eggermont and Robert, 2011; Mansh, 2011; Mellman et al., 2011;
Pandolﬁ et al., 2011). In early phase I trials, PD1 have shown
good activity in a variety of cancer types and have a toxicity
proﬁle that seems safer than ipilimumab (Brahmer et al., 2010).
A recent clinical trial with the longest follow-up of melanoma
patients treated with ipilimumab has shown that ipilimumab can
induce durable, potentially curative tumor regression in a small
percentage of patients with metastatic melanoma (Prieto et al.,
2012).
It has become increasingly clear that tumor microenvironment
plays a crucial role in the control of immune protection and
contains many overlapping mechanisms to evade antigenic spe-
ciﬁc immunotherapy (Zou, 2005; Nagaraj and Gabrilovich, 2007;
Marigo et al., 2008). Several reports underscore the contribu-
tion of the microenvironment to tumor development and it is
well admitted that tumors are not merely masses of neoplastic
cells, but instead, are complex tissues composed of both non-
cellular (matrix proteins) and cellular components, in addition
to the ever-evolving neoplastic cells. Tumor microenvironment
is a complex and highly dynamic environment, providing very
important clues to tumor development and progression (Petrulio
et al., 2006). In the context of microenvironment complexity and
plasticity, tumor cells orchestrate the modiﬁcation of the microen-
vironment by attracting or activating many non-tumoral cells,
including ﬁbroblasts, blood and lymphatic endothelial cells, bone
marrow-derived cells, immune and inﬂammatory cells. Moreover,
it is now acknowledged that tumor cells and their stroma co-evolve
during tumorigenesis and tumor progression (Hiscox et al., 2011).
Therefore, tumor growth and spread depend as much on the host
response as on the biologic characteristics of the tumor itself and
on the inﬂuence of the tumor microenvironment (Petrulio et al.,
2006).
The hypoxia’s critical role in radio-resistance, chemoresistance,
tumor stemness, and its signiﬁcance as an adverse prognosis fac-
tor have been well established and at present hypoxia-induced
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angiogenesis has become an attractive target for cancer therapy
(Semenza, 2010). Hypoxia-inducible factor (HIF-1α) overexpres-
sion and its associationwithpoor treatment response andoutcome
has been demonstrated in an extensive range of human tumors
(Semenza, 2010; Wilson and Hay, 2011). In addition, a direct link
between tumor hypoxia and tolerance through the recruitment
of regulatory cells has been established (Facciabene et al., 2011).
Hypoxia-induced vascular endothelial growth factor (VEGF) pro-
duced by most tumors plays an important role in tumor angio-
genesis (Takenaga, 2011). It also plays a key role in immune escape
by licensing invasion, metastasis, impacting therapeutic response
and favoring immune escape mechanisms.
Hypoxia is therefore attracting a particular attention in the
ﬁeld of tumor immune biology since hypoxic stress impact angio-
genesis, tumor progression and immune tolerance. Modulating
the stromal hypoxia may constitute in fact a very potent strat-
egy for targeted therapeutic approaches. How peripheral immune
tolerance and angiogenesis programs are closely connected and
cooperate under hypoxic conditions to sustain tumor growth will
be discussed in this article.
HYPOXIA-INDUCED ANGIOGENESIS AND RESISTANCE TO
CYTOTOXIC TREATMENTS
HYPOXIA-INDUCIBLE FACTORS: DETERMINANT FACTORS IN TUMOR
CELL ADAPTATION TO HYPOXIC STRESS
Tumor cells adapt to hypoxic microenvironment by the regulation
of HIFs family of transcription factors. This family is composed
of three members namely HIF-1, HIF-2, and HIF-3. HIFs are a
heterodimeric proteins composed of a constitutively expressed
HIF-β subunit and an O2-regulated HIF-α subunit (Wang et al.,
1995). Both HIF-1α and HIF-2α have common target genes as
well as their respective target genes (Lau et al., 2007). The genes
induced by hypoxia-dependent HIF-1α and HIF-2α play impor-
tant roles in regulating different aspects of tumor biology espe-
cially angiogenesis, cell survival, chemo- and radio-resistance,
proliferation, invasion and metastasis, pH regulation and metab-
olism, resistance to immune system, and maintenance of cancer
stem cells (Keith and Simon, 2007; Lukashev et al., 2007; Keith
et al., 2011).
In thepresence of O2,HIF-1α is hydroxylatedonproline residue
402 and/or 564 by prolyl hydroxylase domain protein 2 (PHD2),
resulting in its interaction with the von Hippel–Lindau (VHL)
protein, which recruits an E3 ubiquitin-protein ligase that even-
tually catalyzes polyubiquitination of HIF-1α thereby targeting
it for proteasomal degradation (Salceda and Caro, 1997). Under
hypoxic conditions, hydroxylation is inhibited and HIF-1α rapidly
accumulates, translocates to the nucleus, dimerizes with HIF-1β
and activates transcription. Similar toHIF-1α,HIF-2α is also regu-
latedbyoxygen-dependent hydroxylation (Patel andSimon,2008).
HIF-1α and HIF-2α differ in their transactivation domains but are
structurally similar in DNA binding and dimerization domains.
HIF-3α lacks the transactivation domain and may function as an
inhibitor of HIF-1α and HIF-2α and its expression is transcrip-
tionally regulated by HIF-1 (Makino et al., 2007). HIF-1α and
HIF-2α are also regulated by several oxygen-independent mech-
anisms involving mutation of VHL, PTEN, BRAF, SDH, FH, and
MITF (Semenza, 2010; Noman et al., 2011c).
HYPOXIA-INDUCED VEGF AS A KEY EVENT IN PROMOTING
ANGIOGENESIS
Growing tumor mass requires neo-vascularization to provide
rapidly proliferating tumor cellswith an adequate supply of oxygen
and metabolites. Diffusion distances from the existing vascula-
ture increases as tumor expands resulting in local hypoxia (Harris,
2002; Brahimi-Horn et al., 2007; Dewhirst et al., 2008). Increasing
evidence shows that the hypoxic stress plays a key role in the reg-
ulation of angiogenesis that is required for invasive tumor growth
and metastasis (Semenza, 2010). HIF-1α stabilization and nuclear
accumulation results in the subsequent activation of a wide range
of target genes belonging to angiogenesis and promoting endothe-
lial cell proliferation, migration, permeability, and survival (Wang
et al., 1995). HIF-2 is also able to promote tumor angiogenesis
through mobilization of circulating progenitor endothelial cells
(Kim et al., 2009) and through VEGF induction (Raval et al.,
2005; Li et al., 2009). HIF-1α and HIF-2α can also be regulated by
oxygen-independent mechanisms leading to increased HIF tran-
scriptional program under normal level of O2 and promoting
tumor growth and angiogenesis (Semenza, 2010). In this regard,
the double allele loss of function (deletion, mutation, CpG island
hypermethylation) VHL−/− gives rise to increased constitutive
level of HIF-1α and/or HIF-2α (Baldewijns et al., 2010). VHL can
also directly regulate the stability of certain mRNAs such as that
of VEGF (Datta et al., 2005) and mRNAs related to growth factor
signaling, suggesting that mRNA changes observed after VHL loss
are not solely due to the subsequent HIF accumulation (Kaelin,
2008).
Although vessel growth andmaturation are complex and highly
coordinated processes requiring the sequential activation of a
multitude of factors, there is a consensus that VEGF signaling
represents a crucial step in tumor angiogenesis (Liao and Johnson,
2007). It should also be noted that antiangiogenic drugs and vas-
cular destructive agents may in turn promote tumor cell invasion
and metastasis in association with drug-induced tumor hypoxia.
HYPOXIA-INDUCED ANGIOGENESIS LEADS TO INCREASED
RESISTANCE TO CYTOTOXIC TREATMENTS
Tumor hypoxia-induced abnormal neo-angiogenesis leads to
increased resistance to cytotoxic treatments. Indeed, tumor ves-
sels are labyrinthine and branched in an irregular and chaotic
manner with uneven diameters due to the compression of their
walls by tumor or stromal cells (Jain, 1988, 2005; Nagy et al.,
2010). These abnormalities in hypoxia-induced tumor vessels have
been found in a wide range of tumor types, in mice both in
transplantable tumors and in spontaneous tumors arising from
exposure to carcinogens or expression of oncogenes (Baluk et al.,
2005; Hamzah et al., 2008; Van de Veire et al., 2010) and in tumors
from patients (Willett et al., 2004; Batchelor et al., 2007). Tumor
vessel blood ﬂow is compromised and stagnant due to increased
vascular resistance and improper vasoregulation (Jain,2005; Fuku-
mura et al., 2010). Similarly hypoxia-induced tumor endothelial
cells are abnormal. Normal vessels are lined with a monolayer of
interconnected endothelial cells, whereas tumor endothelial cells
are often leaky, with wide open junctions and many fenestrations
resulting in limited tissue perfusion (Jain, 1988). These abnor-
mal neo-vessels with leaky walls facilitate the escape of tumor
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cells (Jain, 2005). All these abnormalities lead to a decrease in
uniform and efﬁcient delivery of nutrients and drugs (Jain, 2005;
Jain and Stylianopoulos, 2010) as well as inﬂux of immune cells
(Hamzah et al., 2008). As irradiation and certain chemothera-
peutics rely on the formation of reactive oxidative species to kill
cancer cells, tumor hypoxia also reduces the efﬁcacy of conven-
tional anticancer treatments (Moeller et al., 2007). Thus, it is clear
that hypoxia-induced angiogenesis is responsible for an abnormal
tumor vasculature (Carmeliet and Jain, 2011), which can inﬂu-
ence tumor response to anticancer treatments as well as tumor
inﬁltration by immunocompetent cells.
ROLE OF HYPOXIA-INDUCED VEGF IN MODULATING TUMOR RESPONSE
TO CYTOTOXIC T-LYMPHOCYTES
Wehave shown that hypoxic exposure of tumor cells inhibits autol-
ogous cytotoxic T-lymphocytes (CTL)-mediated lysis (Noman
et al., 2009, 2011b). We provided evidence indicating that HIF-1α
induction and signal transducer and activator of transcription-3
(STAT3) activation are associated with hypoxia-induced lysis inhi-
bition. This suggests a new role for hypoxia-dependent induction
of HIF-1α and activation of STAT3 in tumor resistance to the
immune system.
Signal transducer and activator of transcription-3 activation
within tumor microenvironment is known to be associated with
cytokine-induced proliferation, anti-apoptosis, and transforma-
tion. Moreover, STAT3 modulates the cross-talk between tumor
and immune cells (Wang et al., 2004; Yu et al., 2007). More inter-
estingly, we have shown that VEGF neutralization resulted in the
attenuation of hypoxic tumor target resistance to CTL-mediated
killing (Noman et al., 2009). We have also demonstrated that
STAT3 phosphorylation can be stimulated by autocrine signaling
throughVEGF, suggesting that tumor microenvironment through
hypoxia-induced VEGF may play a key role in the induction of
active form of STAT3. In this regard, it is very likely that STAT3
activation is associated with the regulation of gene expression
potentially involved in the alteration of hypoxic tumor target-
speciﬁc killing. Therefore, understanding how VEGF and other
soluble factors lead to STAT3 activation via the tumor microenvi-
ronment may provide a more effective cancer treatment strategy
for hypoxic tumorswith elevatedP-STAT3 levels. This also suggests
that reduction of VEGF release in tumor microenvironment may
favor induction of a stronger anti-tumor CTL response against
tumors expressingVEGF receptor (VEGFR). In this regard, inhibi-
tion of VEGF may be a valuable adjuvant in the immunotherapy of
cancer (Gabrilovich et al., 1996) pointing to the existence of a syn-
ergy between tumor immunotherapy and antiangiogenic therapy
(Nair et al., 2003).
HYPOXIA INDUCES EPITHELIAL-TO-MESENCHYMAL TRANSITION
Epithelial-to-mesenchymal transition (EMT) is a complex mole-
cular process during which epithelial cells lose their apico-basal
polarity and acquire a mesenchymal and motile phenotype. The
hallmarks of EMT are the down regulation of epithelial mark-
ers (E-cadherin) and the up regulation of mesenchymal markers
(Vimentin, Fibronectin, the transcriptional factors Snail, Slug,
Twist, and Zeb1/2) leading to an organized disassembly of epithe-
lial cell-to-cell contacts enablingmotility and invasiveness (Thiery,
2002). EMT has therefore become a prominent program involved
in carcinogenesis, metastasis, tumor recurrence and resistance
to apoptosis and to chemotherapy (Barrallo-Gimeno and Nieto,
2005, p. 172; Thiery and Sleeman, 2006, p. 173). The activation
of EMT in tumor cells has been reported to be associated with
interactions of tumor cells with tumor-associated stromal cells,
implicatingneoplasticmicroenvironmental stimuli inEMT induc-
tion. In this regard, tumor hypoxia through HIF-1α has recently
been proposed to be an important trigger and modulator of EMT
(Lundgren et al., 2009; Sleeman and Thiery, 2011).
During hypoxic stress, different signaling pathways seem to be
involved in triggering EMT (Jiang et al., 2011). In this regard,
the existence of cooperation between hypoxia and TGFβ signal-
ing resulting in EMT activation has been reported (Schaffer et al.,
2003; Nishi et al., 2004). Recent ﬁndings also demonstrate that,
in breast cancer cells, the Notch pathway plays a role in hypoxia-
activated EMT since its inhibition abrogates hypoxia-mediated
increase in Slug and Snail expression, and decreases cell migra-
tion and invasion (Chen et al., 2010). Lysyl oxidase (LOX) and
the related LOX-like 2 (LOXL2) have recently been reported to
be direct transcriptional targets of HIF-1α that are sufﬁcient to
repress E-cadherin and induce EMTunder hypoxia (Schietke et al.,
2010). Urokinase plasminogen activator receptor (uPAR), another
direct transcriptional target of HIF-1α (Buchler et al., 2009), is
described to be involved in E-cadherin repression and EMTactiva-
tion during hypoxic stress in medulloblastoma cells (Gupta et al.,
2011). Interestingly, Luo et al. (2011) have recently identiﬁed a
hypoxia-response element in close proximity with the minimal
promoter of human and mouse Snail, which binds both HIF-1
and HIF-2 proteins and which activates snail transcription. This
provides new evidence of the direct involvement of HIFs in Snail
activation and EMT-regulation.
It should be noted that EMT contributes to malignancy not
only by enhancing motility, invasiveness, resistance to apoptosis
and drugs, but also by inducing immune escape. In fact, Kudo-
Saito et al. report that Snail expression in melanoma cells resulted
in the impairment of dendritic cell maturation, expansion of T
regulatory cells, and resistance to CTL-mediated lysis. Moreover,
intratumoral targeting of Snail in melanoma signiﬁcantly inhib-
ited tumor growth and metastasis in correlation with an increase
of tumor-speciﬁc tumor-inﬁltrating lymphocytes and of systemic
immune responses (Kudo-Saito et al., 2009). It seems that EMT
program in tumors is able to redirect the immune system toward
immune tolerance. Since hypoxia has been also reported to medi-
ate immune tolerance, the role of EMT factors in this process
remains to be investigated.
TUMOR HYPOXIA PROMOTES ANGIOGENESIS AND IMMUNE
TOLERANCE
It is well known that immune system can effectively inhibit tumor
growth (Zhang et al., 2003; Koebel et al., 2007; Fridman et al.,
2011). However, tumors are known to establish diverse potent
mechanisms,which help them to escape the immune system (Zou,
2005; Nagaraj and Gabrilovich, 2007; Marigo et al., 2008; Hamai
et al., 2010). Emerging evidence indicates a link between hypoxia-
induced angiogenesis and tolerance to immune system (Manning
et al., 2007; Buckanovich et al., 2008; Tartour et al., 2011). Tumor
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hypoxia drives angiogenesis by inducing synthesis of VEGF and
other pro-angiogenic factors in tumor cells via HIFs and promotes
immunosuppression (Noman et al., 2009, 2011a). The association
between angiogenesis and immunosuppression comes from the
immunosuppressive activities of angiogenic factors such as VEGF,
a cytokine secreted by most tumors (Toi et al., 1996a,b), making
it a critical actor in tumor angiogenesis and immune tolerance
(Motz and Coukos, 2011). Hypoxic zones in tumors attract a vari-
ety of immune cells in which HIF stabilization is associated with
the acquisition of both pro-angiogenic and immunosuppressive
phenotype (Noman et al., 2011c).
MYELOID CELLS
Myeloid cells are perhaps the best-studied cell types in terms of
their ability to promote immunosuppression and angiogenesis in
tumors (Gabrilovich and Nagaraj, 2009; Motz and Coukos, 2011).
Tumor-associated macrophages
Macrophages constitute a major component of the immune inﬁl-
trate seen in tumors (Bingle et al., 2002). In the tumor microen-
vironment, they differentiate into tumor-associated macrophages
(TAM) with expression of TAM markers such as CD206 (Man-
tovani et al., 2002). High TAM numbers in tumors in major-
ity of cases are correlated with reduced survival (Bingle et al.,
2002). Exposure of TAM to tumor-derived cytokines such as IL-
4 and IL-10 is able to convert them into polarized type II or
M2 macrophages with immune-suppressive activities and pro-
angiogenic effects, resulting in tumor progression (Mantovani
et al., 2002). TAM are found to be preferentially located in tumor
hypoxic areas, where they accumulate HIF-1 and HIF-2 and up
regulate VEGF and other pro-angiogenic factors (Lewis et al.,
2000). The relative contribution of HIF-1 and HIF-2 in the regu-
lation of gene expression in TAM is not yet completely elucidated.
In human macrophages, HIF-2 has been reported to be a cru-
cial inducer of pro-angiogenic molecules (White et al., 2004).
In another study, Werno et al. (2010) proposes that HIF-1 is
indispensable for angiogenic-promoting properties of TAM, at
least in murine macrophages. Besides this angiogenesis promoting
activity, HIF-1α was also reported to be crucial for macrophage-
mediated inhibition of T cells in hypoxic conditions (Doedens
et al., 2010). In hypoxic areas of tumors, TAM also up-regulate the
expression of MMP-7 protein in hypoxic areas of tumors (Burke
et al., 2003). MMP-7 is known to cleave the Fas ligand from neigh-
boring cells, making tumor cells less responsive to lysis by NK and
T cells (Fingleton et al., 2001). MMP-7 is also known to stimulate
endothelial cell proliferation and migration, which can support
tumor angiogenesis (Nishizuka et al., 2001).
Myeloid derived suppressor cells
Myeloid derived suppressor cells (MDSCs) have also been demon-
strated to directly promote angiogenesis (Yang et al., 2004) and
immune tolerance (Gabrilovich and Nagaraj, 2009). In tumor
bearing hosts, tumor-derived factors such as VEGF, GM-CSF,
prostaglandins also restrainDCmaturation andpromote the accu-
mulation of MDSCs in tumoral tissues and secondary lymphoid
organs (Gabrilovich, 2004). In these sites, MDSCs induce T cell
anergy, restrain the effector phase of the CD8+ T cell, and can
promote antigen-speciﬁc T reg proliferation (Gabrilovich, 2004;
Seraﬁni et al., 2008). Moreover, HIF-1α has been directly shown
to regulate the function and differentiation of MDSC within the
hypoxic tumor microenvironment (Corzo et al., 2010). A cross-
talk between MDSC and macrophages has been reported, propos-
ing that MDSC down-regulate IL-12 production by macrophages
and increase their own production of IL-10 in response to sig-
nals from macrophages. This interaction between MDSC and
macrophages polarizes classically activated (M1) macrophages
toward a type 2 and immunosuppressive phenotype and accen-
tuates the M2 phenotype of M2 macrophages, which is likely
to establish an environment that skew CD4+ and CD8+ T cell
immunity toward a tumor-promoting type 2 response (Trinchieri,
2003). As a result, MDSC directly and through their cross-talk
with macrophages, suppress both adaptive and innate anti-tumor
immunity, which facilitate tumor growth. MDSC also have pro-
angiogenic activities that can mediate tumor refractoriness to
anti-VEGF treatment (Shojaei et al., 2007).
Dendritic cells
The dendritic cell subset is also diverted by VEGF from its
highly specialized antigen-presenting and T cell activating func-
tions. Indeed, production of VEGF by human tumors inhibits
the functional maturation of dendritic cells and thereby pro-
motes immune escape of tumor cells (Gabrilovich et al., 1996).
Recombinant VEGF administered to tumor-free mice resulted
in repressed dendritic cell development associated with accu-
mulation of Gr-1+ immature myeloid-derived suppressor cells
(MDSC) that inhibit T cell functions (Gabrilovich et al., 1998),
illustrating the proper immune-suppressive functions of VEGF.
Tumor-associated myeloid dendritic cells, in response to tumor-
derivedVEGF, increase the expression of PDL-1which is a negative
regulator of T cell function (Curiel et al., 2003). Moreover, anti-
VEGF therapywas associatedwith a decrease in immaturemyeloid
and dendritic cells in patients (Osada et al., 2008).
LYMPHOCYTES
Lymphocytes play a crucial role in immunosuppression and tol-
erance (Fridman et al., 2011). In an ovarian cancer model, very
recently, it has been shown that hypoxia promotes the recruitment
of the immunosuppressive CD4+ CD25+ FOXP3+ T regula-
tory cells (T reg) through the induction of CCL28 expression
by hypoxic tumor cells. T reg in turn secrete VEGF, contribut-
ing to the VEGF pool in the tumor microenvironment and to
immune tolerance (Facciabene et al., 2011). Moreover, CD4-
deﬁcient mice have an impaired angiogenesis response to hypoxia
during ischemia (Stabile et al., 2003). Moreover VEGF target-
ing reduces intratumoral T regulatory cells and increases the
efﬁcacy of cancer immunotherapy in B16 melanoma and the
CT26 colon carcinoma models (Li et al., 2006). In addition, an
inverse correlation between angiogenesis and tumor-inﬁltrating
T cells has already been reported (Zhang et al., 2003; Buck-
anovich et al., 2007, 2008; Kandalaft et al., 2009). Other lym-
phocyte cells (including regulatory B cells, NK cells, and NKT
cells) with immunosuppressive functions have been reported to
produce VEGFA (Motz and Coukos, 2011). However, the pre-
cise role of these cells in tumor angiogenesis remains largely
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FIGURE 1 | Role of hypoxia-inducedVEGF in mediating immune
tolerance. Diverse effects of hypoxia-induced VEGF on different
components of the immune system (TAM, MDSC, DC, CTL, andT reg).
In general, hypoxia-induced VEGF pool in tumor microenvironment
(VEGF secreted by hypoxic tumor cells, TAM, MDSC, DC, andT reg)
ampliﬁes the activity of TAM, MDSC, andT reg while suppressing the
function of CTL and delaying the maturation of DC cells. TAM,
tumor-associated macrophages; MDSC, myeloid derived suppressor
cells; DC, dendritic cells; CTL, cytotoxic T-lymphocyte; T reg, T
regulatory cells.
unknown. Therefore, the exact contribution of these lymphocytes
inmediatingVEGF-induced immune suppression requires further
investigation.
Different facets of VEGF-induced immunosuppression in
diverse cell types in hypoxic tumor microenvironment is sum-
marized in Figure 1.
HYPOXIA, PRO-INFLAMMATORY MEDIATORS, AND IMMUNE
SUPPRESSION
Hypoxia induces both angiogenesis and immunosuppression also
by upregulating COX-2 in tumor cells (Greenhough et al., 2009).
COX-2 is an inﬂammatory enzyme converting arachidonic acid
into prostaglandin PGE2 which has angiogenic properties by
promoting VEGF expression (Jain et al., 2008) and immuno-
suppressive functions by causing, in cooperation with hypoxia-
induced increased extra-cellular adenosine, cAMP accumulation
in effector T cells resulting in the suppression of their anti-tumor
functions (Whiteside et al., 2011). PGE2 can also inhibit tumor
immunity by inhibiting dendritic cell maturation, their expres-
sion of co-stimulatory molecules, and their production of IL-12.
In addition, PGE2 enhances the suppressive activity of T reg and
is involved in the conversion of CD4+ CD25− into T reg. Finally,
PGE2 can stimulate the immunosuppressive functions of MDSC
by binding the EP-4 receptor (Rodriguez et al., 2005; Sinha et al.,
2007; Seraﬁni, 2010).
Thus hypoxia connects peripheral immune tolerance and
angiogenic programs to sustain tumor growth. The counter-
activation of tolerance mechanisms at the site of tumor hypoxia is
therefore a crucial condition for maintaining the immunological
escape of tumors.
THERAPEUTIC INTERVENTIONS TARGETING ANGIOGENESIS
Hypoxia-inducedVEGFproducedbymost tumors plays an impor-
tant role in tumor angiogenesis (Takenaga, 2011). Recognition
of the VEGF pathway as a key regulator of angiogenesis has led
to the development of several VEGF-targeted molecules (Porta
et al., 2011). These molecules include neutralizing antibodies to
VEGF (Escudier et al., 2008) or VEGFRs, mTOR kinase inhibitors
(Azim et al., 2010), and tyrosine kinase inhibitors (TKIs; Porta
et al., 2011) with selectivity for VEGFRs. The pioneers in the
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ﬁeld of angiogenesis inhibitors are bevacizumab (an anti-VEGF
monoclonal antibody that binds speciﬁcally to the VEGF ligand
and neutralizes its activity; Ferrara et al., 2004) and two multi-
targeted kinase inhibitors (sorafenib and sunitinib; non-speciﬁc
small molecules that inhibit multiple kinase receptors; Zhong and
Bowen, 2011). Indirectly, the macrocyclic lactones temsirolimus
and everolimus, inhibit also VEGF (Azim et al., 2010). These mol-
ecules inhibit the mTOR complex formation targeting mTORC1
that inhibits HIF-1α expression and consequently inhibits HIF-
1α dependent VEGF transcription decreasing angiogenesis (Azim
et al., 2010). These angiogenesis inhibitors have proven their ther-
apeutic efﬁcacy in several mouse models of cancer and in a large
number of human cancers (Porta et al., 2011). However, clini-
cal beneﬁts are often followed by a restoration of tumor growth
and progression (Burger et al., 2011; Perren et al., 2011). The
Bevacizumab-chemotherapy combination seems to be successful
in second-line settings in the treatment of patients with advanced
colorectal cancer, compared to the disappointing efﬁcacy of com-
bining bevacizumab with chemotherapy in the ﬁrst-line treatment
of the patients (Jenab-Wolcott and Giantonio, 2010). Several
intrinsic and adaptive mechanisms were shown to be involved
in resistance to angiogenic therapy (Bergers and Hanahan, 2008).
Antiangiogenic therapy can lead to hypoxia as a compensatory
mechanism (Casanovas et al., 2005; Bergers and Hanahan, 2008).
It is now clear that hypoxia-induced by angiogenesis inhibitors
might further elevate VEGF and other pro-angiogenic factors
expression in tumors (Shaked et al., 2005; Mancuso et al., 2006).
Sathornsumetee et al. (2008) have shown that hypoxic proﬁles
can predict survival in malignant astrocytoma patients treated
with bevacizumab. Another mechanism underlying resistance to
anti-VEGF therapy involves inﬁltration of various pro-angiogenic
bone marrow-derived cells, in part through increases in HIF-1α
and its downstream effectors such as VEGF (Ceradini et al., 2004;
Shaked et al., 2006). In a metastatic colorectal cancer model, beva-
cizumab therapy improved the impairment of lymphocyte subsets,
especially for T cells. These effects correlated with more favorable
clinical outcome (Manzoni et al., 2011). Interestingly, anti-VEGF
agents can have contradictory effects on immune system (Seliger
et al.,2010). Sorafenib appears to impair,while sunitinib stimulates
terminal DC maturation (Hipp et al., 2008). Sunitinib induces Th-
1 immune response (IFN-γ expression) while reducing T reg in
renal cell carcinoma patients (Finke et al., 2008). Sunitinib, but not
Sorafenib has been shown to inhibit MDSC immune-suppressive
activity and reduces MDSC and T reg circulating numbers (Ko
et al., 2009). Another study has shown that sunitinib adminis-
tration in mouse renal cell carcinoma tumor bearing mice led to
the inhibition of Stat3 in tumor-associatedmyeloid cells, including
dendritic cells andMDSCs,whichwas accompanied by a reduction
of tumor T reg (Xin et al., 2009). Du et al. (2008) have shown that
impairment of VEGF signaling leads to an adaptive pro-invasive
tumor phenotype.
A better understanding of the complex interaction between
cancer cells, immune system and anti-VEGF agents is therefore
needed for improving and sustaining the beneﬁts of antiangio-
genic therapy.
CONCLUSION
Advances in immunology and molecular biology have shown
that cancers are potentially immunogenic and that host immune
responses inﬂuence survival (Galon et al., 2006). However,
immune surveillance and activation is frequently ineffective in
preventing and/or controlling tumor growth. In fact, an active and
bi-directional molecular cross-talk between tumor microenviron-
ment and host cells has profound implications for immunological
recognition and progression of tumor cells (Petrulio et al., 2006;
Lorusso and Ruegg, 2008). The cross-talk between tumor cells
and stromal cells within the tumor microenvironment medi-
ates tumor initiation, progression, and response to anticancer
therapy. In this regard, microenvironmental components includ-
ing hypoxia appear to regulate gene expression in tumor cells
thereby directing the tumor toward aggressiveness, angiogenesis,
and metastasis. It is well documented that inﬂammation is an
important part of hypoxic tumor microenvironment (Eltzschig
and Carmeliet, 2011). Increasing evidence suggest the existence
of a link between hypoxic stress and several inﬂammatory mol-
ecules (PEG2, COX-2, chemokines, and cytokines) responsible
for tumor initiation and progression. These pro-inﬂammatory
mediators not only support tumor survival and expansion but
also the function of several immune cells notably dendritic and
effector cells (Chow et al., 2011). Therefore, a well-integrated
understanding of this intricate microenvironment may offer
new opportunities for therapeutic intervention. Recent insights
into cellular and molecular cross-talk suggest a model in which
hypoxia, HIF, VEGF, and several other HIF target genes partici-
pate in the coordinated collaboration between tumor, endothelial,
inﬂammatory/hematopoietic, and circulating endothelial precur-
sor cells to enhance and promote tumor vascularization. Given
its central role in tumor progression and resistance to therapy,
tumor hypoxia might well be considered as one potential tar-
get that has yet to be exploited in oncology. Its targeting may
be therefore an innovative approach to design new approaches
in cancer therapy. Recently, a growing number of drugs that
inhibit HIF-1 have been identiﬁed and validated as anticancer
agents (Semenza, 2010; Wilson and Hay, 2011). It is also becom-
ing evident that characterizing the tumor microenvironment can
provide important prognostic and predictive information about
tumors, independently of the tumor cell phenotype. Whether
the inhibition of hypoxic signaling pathways in different com-
partments of the solid tumor microenvironment will open new
therapeutic opportunities in cancer immunotherapy has to be
established.
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